A CpG region, biomarker, reagent and application
By revealing DNA hypermethylation in a specific region of the KCNH5 gene in colorectal cancer, a highly sensitive method for early screening and recurrence monitoring of colorectal cancer is provided, overcoming the shortcomings of existing technologies and achieving a high detection rate for advanced adenomas and late-stage colorectal cancer, thus providing a new diagnostic target.
Patent Information
- Application Number
- CN202611172082.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-04
- Publication Date
- 2026-11-10
AI Technical Summary
Existing technologies lack accurate, convenient, non-invasive, or minimally invasive methods for early screening of colorectal cancer. Fecal testing has low sensitivity, colonoscopy is highly invasive, and there are no systematic reports on the DNA methylation of the KCNH5 gene in colorectal cancer using liquid biopsy techniques.
This invention provides a CpG region biomarker associated with colorectal cancer, including a differentially methylated sequence of the KCNH5 gene located in a specific region of chromosome 14 of the human reference genome hg19. Through a specific primer probe set and blocking oligonucleotides, combined with sulfite treatment technology, it enables highly sensitive detection of trace amounts of methylated cfDNA in liquid samples such as plasma.
It achieves highly sensitive detection for early screening and recurrence monitoring of colorectal cancer, especially high detection rate of advanced adenomas and late-stage colorectal cancer. The detection results are stable and reliable, overcoming errors caused by inter-sample differences and providing new diagnostic targets.
Smart Images

Figure CN123063522A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biomarker detection technology for colorectal cancer and advanced adenomas, specifically to a CpG region, biomarker, reagent, and application. Background Technology
[0002] Colorectal cancer is a major disease posing a serious threat to human health worldwide. According to the 2020 global cancer statistics released by the International Agency for Research on Cancer (IARC) of the World Health Organization, colorectal cancer ranks third in incidence and second in mortality among all malignant tumors. The incidence and mortality rates of colorectal cancer are also showing a rapid upward trend year by year, and the age of onset is becoming younger, making it a significant public health issue. The prognosis of colorectal cancer is closely related to the stage at diagnosis. The five-year survival rate for patients with early-stage (stage I) colorectal cancer can exceed 90%, while the five-year survival rate for patients with advanced-stage (stage IV) cancer drops sharply to around 10%. Therefore, early detection and early intervention of colorectal cancer are crucial to reducing its mortality rate and improving patient prognosis.
[0003] Currently, the recommended colorectal cancer screening methods in clinical practice mainly fall into two categories: fecal-based testing and structural examination. Fecal occult blood testing is the most widely used initial screening method, but its sensitivity is limited, easily affected by diet, medication, and non-tumor gastrointestinal bleeding, and its detection rate for early-stage cancer and precancerous lesions (such as high-grade adenomas) is not high. Fecal DNA testing (such as multi-target FIT-DNA testing) has improved sensitivity, but its high cost and technical complexity limit its widespread adoption. Colonoscopy is the "gold standard" for colorectal cancer screening and diagnosis, allowing direct observation of mucosal lesions and enabling biopsy or treatment. However, its use as a screening tool has significant limitations: the procedure is invasive, requires strict bowel preparation, carries risks of complications such as perforation and bleeding, consumes significant medical resources, and has generally low acceptance and compliance among the population. These limitations make the development of accurate, convenient, non-invasive, or minimally invasive novel detection technologies an urgent need for clinical practice and research.
[0004] In recent years, the rise of liquid biopsy technology has brought revolutionary hope to the early diagnosis of cancer. Among these advancements, epigenetic alterations based on circulating cell-free DNA, particularly aberrant methylation of CpG islands in gene promoter regions, have become highly promising tumor biomarkers. DNA methylation is one of the key epigenetic mechanisms regulating gene expression in cells. During cancer development, methylation patterns across the entire genome become significantly disrupted, primarily manifested as overall genome hypomethylation and hypermethylation of CpG islands in specific gene promoter regions. The latter often leads to transcriptional silencing of related tumor suppressor genes, thereby promoting tumor development and progression. Compared to gene mutations, abnormal DNA methylation can appear in the early stages of tumor development, exhibits tissue specificity and relative stability, and is easily detected from minute samples using sensitive techniques such as PCR. These characteristics make it an ideal biomarker for early diagnosis and liquid biopsy.
[0005] The KCNH5 gene, also known as EAG2, encodes a voltage-gated potassium channel protein. This channel plays a crucial role in the development and function of the central nervous system, and its aberrant expression is associated with epilepsy and nervous system tumors. In recent years, sporadic studies have suggested that KCNH5 may be aberrantly expressed in certain solid tumors, such as breast cancer. However, to date, there have been no systematic reports, either domestically or internationally, on the role of the KCNH5 gene in the development and progression of colorectal cancer and advanced adenomas, particularly at the epigenetic regulatory level. Whether it exhibits characteristic DNA methylation changes in colorectal cancer and advanced adenomas, and whether such changes have diagnostic and clinical application value, remains entirely unknown. Discovering and validating such novel methylation targets unrelated to known common biomarkers is of great significance for enriching the molecular biomarker library for colorectal cancer and advanced adenomas and developing more specific diagnostic tools.
[0006] Therefore, existing technologies still need to be improved and developed. Summary of the Invention
[0007] The technical problem to be solved by the present invention is to provide a CpG region, biomarker, reagent and application related to colorectal cancer and advanced adenoma, in view of the above-mentioned defects of the prior art. It reveals the correlation between DNA hypermethylation of KCNH5 gene in a specific region and colorectal cancer or advanced adenoma, and can be effectively applied to early screening and recurrence monitoring of colorectal cancer.
[0008] The technical solution adopted by this invention to solve the technical problem is as follows: This application provides a CpG region associated with colorectal cancer and advanced adenoma, wherein the CpG region is located in the 63512023-63512996 nucleotide range of the positive strand of chromosome 14 of the human reference genome hg19.
[0009] This application provides a biomarker associated with colorectal cancer and advanced adenoma, comprising the KCNH5 gene sequence with differential methylation levels in the CpG region described above.
[0010] This application provides a reagent for detecting the methylation level of the CpG region described above. The reagent includes two sets of specific primer and probe sets, one set of internal reference gene ACTB primer and probe sets, and blocking oligonucleotides, for specifically amplifying and detecting the methylation target sequence of the KC group NH5 gene after sulfite treatment. The upstream primer, downstream primer, and probe sequences of the first set of specific primers and probes are as follows: Upstream primer: 5'-GTGTTTCGCGGAGTTTGTAGT-3'; Downstream primer: 5'-CGCCGCTACCCAAACTAT-3'; Probe: 5'-TCGAGTTTCGTGTGCGGTATCG-3'; The upstream primer, downstream primer, and probe sequences of the second set of specific primers and probes are as follows: Upstream primer: 5'-GTAGGCGTATTGTGTTTCGC-3'; Downstream primer: 5'-CGCCGCTACCCAAACTATAA-3'; Probe: 5'-TCGAGTTTCGTGTGCGGTATCG-3'; The upstream primer, downstream primer, and probe sequences of the ACTB internal reference gene primer and probe set are as follows: Upstream primer: 5'-AGTAAGTTTTTTGGATTGTGAAT-3'; Downstream primer: 5'-CAATAAAACCTACTCCTCCCTT-3'; Probe: 5'-CCACCCAACACACAATAACAAACACA-3'; The sequence of the blocking oligonucleotide is: 5'-TGTGGAGTTTGTAGTTTTTGAGTTTTGTGTGTGG-3'; The two sets of specific primer and probe sets share the same blocking oligonucleotide.
[0011] Preferably, the reagent is suitable for detecting the target region using one or more of the following methods: methylation-specific PCR, bisulfite sequencing, methylation-specific microarray, whole-genome methylation sequencing, pyrosequencing, methylation-specific high-performance liquid chromatography, methylation-specific high-resolution melting curve method, methylation-sensitive restriction endonuclease method, and methylation detection platform based on real-time quantitative PCR.
[0012] Preferably, it also includes a system comparison; The systemic controls included sulfite-treated colorectal cancer cell line DNA as a positive control and peripheral blood genomic DNA from healthy individuals as a negative control.
[0013] This application provides the use of a reagent for detecting the methylation level of the CpG region described above in the preparation of a colorectal cancer diagnostic kit.
[0014] Preferably, the average methylation level of at least 8 CpG sites contained in the CpG region in colorectal cancer patients is significantly higher than that in healthy individuals.
[0015] Preferably, the sample used to detect the methylation level of the CpG region is DNA that has undergone sulfite conversion.
[0016] Preferably, the test sample includes colorectal cancer tissue, adjacent tissue, plasma, serum, feces, or saliva.
[0017] Preferably, the application is based on Taqman qPCR detection technology.
[0018] Compared with existing technologies, the CpG region, biomarker, reagent, and application provided by this invention have the following beneficial effects: This application reveals the correlation between DNA hypermethylation of the KCNH5 gene in a specific region and colorectal cancer and advanced adenoma, providing a novel diagnostic target independent of existing biomarkers.
[0019] This application achieves ultra-high sensitivity detection of trace amounts of methylated cfDNA in liquid samples such as plasma, greatly improving the detection capability of early cancer and minimal residual disease.
[0020] Clinical trials have confirmed that the KCNH5 gene sequence with differential methylation levels is stably present in the plasma of patients with colorectal cancer and advanced adenomas, and its detection level is correlated with tumor stage and the occurrence of advanced adenomas, showing good application potential in early screening and recurrence monitoring.
[0021] At the same time, the detection rate for advanced colorectal cancer samples (stage III and IV) is extremely high, approaching 100%.
[0022] The primer and probe set provided by this invention has high specificity. When used in conjunction with the internal reference gene, it effectively overcomes the errors caused by differences in DNA extraction efficiency and sulfite conversion efficiency among samples, resulting in stable and reliable detection results. Attached Figure Description
[0023] Figure 1 This is the ROC curve of the kit in plasma samples of advanced adenoma.
[0024] Figure 2 This is the ROC curve of the kit in colorectal cancer plasma samples. Detailed Implementation
[0025] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs; the terminology used herein in the specification of the application is for the purpose of describing particular embodiments only and is not intended to be limiting of the application; the terms "comprising" and "having," and any variations thereof, in the specification, claims, and foregoing drawings of this application are intended to cover non-exclusive inclusion. The terms "first," "second," etc., in the specification, claims, or foregoing drawings of this application are used to distinguish different objects, not to describe a particular order.
[0026] In this document, the term "embodiment" means that a particular feature, structure, or characteristic described in connection with an embodiment may be included in at least one embodiment of this application. The appearance of this phrase in various places throughout the specification does not necessarily refer to the same embodiment, nor is it a separate or alternative embodiment mutually exclusive with other embodiments. It will be explicitly and implicitly understood by those skilled in the art that the embodiments described herein can be combined with other embodiments.
[0027] This invention provides a CpG region associated with colorectal cancer and advanced adenoma, wherein the CpG region is located in the 63512023-63512996 nucleotide range of the positive strand of chromosome 14 of the human reference genome hg19.
[0028] This application provides a biomarker associated with colorectal cancer and advanced adenoma, comprising the KCNH5 gene sequence with differential methylation levels in the CpG region described above.
[0029] Analysis of colorectal cancer methylation profiles in the Common Cancer Genome Database (TCGA) revealed that the methylation level of a specific CpG region (chr14:63512023-63512996, hg19) in the KCNH5 gene promoter region was abnormally elevated in colorectal cancer tissues.
[0030] Validation via TBS sequencing of paraffin-embedded colorectal cancer samples (cancer tissue and adjacent normal tissue), leukocyte samples, and negative and positive cell lines confirmed a significant increase in methylation levels at certain sites within the specific CpG region of the aforementioned cancer tissue. This region contains a dense CpG cluster, and its hypermethylation status is correlated with the clinicopathological features of colorectal cancer.
[0031] This application provides a reagent for detecting the methylation level of the aforementioned CpG region. The reagent comprises a carefully designed combination of oligonucleotides capable of specifically recognizing and amplifying the methylated target sequence after sulfite conversion. Specifically, this invention designs multiple pairs of specific primers and corresponding double-quenched fluorescent probes. These oligonucleotides exhibit high specificity for the sulfite-treated sequence, effectively distinguishing between methylated and unmethylated alleles, ensuring detection accuracy. Furthermore, nucleotide combinations are provided for detecting the upstream and downstream primers and fluorescent probes of the internal reference gene ACTB. The reagent may include a DNA extraction module, a sulfite conversion module, a PCR amplification detection module, and necessary positive, negative, and quantitative standard controls, providing clinical laboratories with a complete, standardized, and easy-to-use detection solution.
[0032] The design and synthesis process of primers and probes for detecting methylation of the KCNH5 gene target region is as follows: Based on the target sequence of the KCNH5 gene promoter region (chr14:93906541-93906730, sequence after sulfite conversion), three pairs of specific primers and corresponding TaqMan probes were designed (sequences are shown in Table 1 below), and primers and probes for the internal reference gene ACTB were designed as controls.
[0033] Table 1. Summary of sequences in nucleotide combinations 1–6 The procedure for detecting the methylation level of KCNH5 sites in colorectal cancer tissue samples is as follows: 1. Sample collection Paraffin-embedded samples (including cancerous and adjacent tissues) were collected from 40 patients with pathologically confirmed early-stage (I and II) and advanced-stage (III and IV) colorectal cancer at a hospital. The collection process was approved by the ethics committee, all volunteers signed informed consent forms, and all samples were anonymized.
[0034] 2. Sample DNA extraction and sulfite conversion The applicant's developed "Nucleic Acid Extraction or Purification Reagent (Guangdong-Shenzhen Medical Device Registration No. 20251021)" was used to extract and convert paraffin DNA samples to sulfite. In this process, unmethylated cytosine (C) was converted to uracil (U), while methylated cytosine remained unchanged. Uracil paired with adenine (A) in subsequent PCR steps, and cytosine paired with guanine (G), thus distinguishing between methylated and unmethylated sequences.
[0035] 3. Quantitative PCR reaction for methylation Using the bisulfite-converted DNA sample as a template, primer pairs and probes for detecting the KCNH5 gene were used. Methylation-based quantitative PCR was performed using the primer pairs and probes described in Table 1, following the PCR reaction system in Table 2 and the PCR reaction conditions in Table 3. In addition, primer pairs and probes for the internal control gene ACTB were added to the PCR reaction system to amplify the ACTB gene sequence, thereby monitoring the presence of PCR inhibitors and the proper functioning of the reaction system (reagents, PCR program, fluorescence collection, etc.).
[0036] Table 2 PCR reaction system Table 3 PCR reaction conditions Negative and positive controls: When testing samples, negative and positive controls should also be tested simultaneously. The DNA template in the negative control tube is extracted from Jurkat cells, and the DNA template in the positive control tube is extracted from A549 cells.
[0037] Ct value reading: After PCR is completed, adjust the baseline. Set the fluorescence value 1-2 cycles in advance of the minimum Ct value of the sample in one PCR as the baseline value. Set the threshold at the inflection point of the S-shaped amplification curve to obtain the Ct value of each gene in the sample.
[0038] 4. Analysis of PCR results.
[0039] The above experiments verified that the KCNH5 gene sequence with differential methylation levels is stably present in the plasma of colorectal cancer patients, and its detection level is correlated with tumor stage, showing good application potential in early screening and recurrence monitoring.
[0040] In specific implementation, the reagent is suitable for one or more of the following methods to detect the target region: methylation-specific PCR, bisulfite sequencing, methylation-specific microarray, whole-genome methylation sequencing, pyrosequencing, methylation-specific high-performance liquid chromatography, methylation-specific high-resolution melting curve method, methylation-sensitive restriction endonuclease method, and methylation detection platform based on real-time quantitative PCR.
[0041] In practice, the system also includes a control group; the system control group includes sulfite-treated colorectal cancer cell line DNA as a positive control and peripheral blood genomic DNA from healthy individuals as a negative control.
[0042] This application provides the use of a reagent for detecting the methylation level of the CpG region described above in the preparation of diagnostic kits for colorectal cancer or advanced adenoma.
[0043] In practice, colorectal cancer patients showed significantly higher average methylation levels at at least eight CpG sites within the CpG region compared to healthy individuals.
[0044] In practice, the sample used to detect the methylation level of the CpG region is DNA that has undergone sulfite conversion.
[0045] In practice, the test samples include colorectal cancer tissue, adjacent tissue, plasma, serum, feces, or saliva.
[0046] In practice, the application is based on Taqman qPCR detection technology, which achieves ultra-high sensitivity detection of trace methylated cfDNA in liquid samples such as plasma, greatly improving the detection capability of early cancer and minimal residual lesions.
[0047] The kit described in this application shows the following detection effects on rectal cancer and advanced adenoma: Blood samples were collected from 88 patients clinically and pathologically diagnosed with advanced adenomas, 76 patients with stage 0-II colorectal cancer, 97 patients with stage III-IV colorectal cancer, and 57 healthy individuals from a certain hospital. The sample collection process was approved by the ethics committee, and all patients signed informed consent forms. All samples were anonymized. DNA extraction and bisulfite conversion of plasma samples were performed according to the methods provided in the examples. Fluorescent PCR detection was performed using primer-probe combinations specific to the nucleotide combinations in the examples. The PCR results are shown in Table 3.
[0048] The diagnostic efficacy of each detection region for advanced adenoma samples, colorectal cancer samples, and normal samples was evaluated using SPSS software and ROC analysis. During the analysis, the state variables for advanced adenoma and colorectal cancer samples were recorded as "1", and the state variables for normal samples were recorded as "0". AUC as follows: Figure 1 and Figure 2 As shown.
[0049] Figure 1 The AUC region below the curve is shown in the table below.
[0050] Figure 2 The AUC region below the curve is shown in the table below.
[0051] Based on the two tables above, their diagnostic capabilities are: Ct1 > Ct2 The AUC of Ct1 (0.925) is greater than that of Ct2 (0.919), indicating that Ct1 is slightly more accurate in screening / diagnosing colorectal cancer or advanced adenomas.
[0052] The two curves have similar shapes: the sensitivity of both curves rises directly to above 0.8 at the starting point, which means that the two indicators can detect colorectal cancer or adenoma patients with high sensitivity under appropriate threshold values, and the false negative rate is very low.
[0053] Both indicators had a p-value of 0.000, indicating that there were no positive results due to random errors, and the experimental data were reliable.
[0054] Table 3 shows the detection sensitivity and specificity of the kits in plasma samples in the examples. This embodiment demonstrates that sequences 1 and 2 exhibit excellent differentiation for colorectal cancer from early to late stages, with sensitivities of 57.95% and 62.5% for advanced adenomas, respectively. Improving the detection rate of adenomas is crucial for reducing the incidence and mortality of colorectal cancer. Furthermore, for advanced colorectal cancer samples, sequence 1 achieved a detection rate of 98.97%, and sequence 2 achieved a detection rate of 100%, demonstrating extremely high detection rates for advanced samples.
[0055] The biomarkers and reagents of this application can be used to prepare early screening kits, auxiliary diagnostic kits, prognostic risk assessment kits, or postoperative recurrence monitoring kits for colorectal cancer, as components of colorectal cancer risk prediction models, and as potential biomarkers for evaluating the efficacy of treatment in colorectal cancer patients.
[0056] In summary, this invention discloses a CpG region, biomarker, reagent, and application related to colorectal cancer and advanced adenoma. It reveals the correlation between DNA hypermethylation of the KCNH5 gene in a specific region and colorectal cancer, providing a novel diagnostic target independent of existing biomarkers. Clinical trials have confirmed that the KCNH5 gene sequence with differential methylation levels is stably present in the plasma of patients with colorectal cancer and advanced adenoma, and its detection level is correlated with tumor stage. It shows good application potential in early screening and recurrence monitoring. At the same time, the primer and probe set provided by this invention has high specificity and, in combination with the internal reference gene, effectively overcomes the errors caused by differences in DNA extraction efficiency and sulfite conversion efficiency between samples, resulting in stable and reliable detection results.
[0057] Obviously, the embodiments described above are only some embodiments of this application, not all embodiments. The accompanying drawings show preferred embodiments of this application, but do not limit the patent scope of this application. This application can be implemented in many different forms; rather, the purpose of providing these embodiments is to provide a more thorough and comprehensive understanding of the disclosure of this application. Although this application has been described in detail with reference to the foregoing embodiments, those skilled in the art can still modify the technical solutions described in the foregoing specific embodiments, or make equivalent substitutions for some of the technical features. Any equivalent structures made using the content of this application's specification and drawings, directly or indirectly applied to other related technical fields, are similarly within the scope of patent protection of this application.
Claims
1. A CpG region associated with colorectal cancer and advanced adenoma, characterized in that, The CpG region is located in the nucleotide interval 63512023-63512996 of the positive strand of chromosome 14 of the human reference genome hg19.
2. A biomarker associated with colorectal cancer and advanced adenoma, characterized in that, Includes the KCNH5 gene sequence with differential methylation levels within the CpG region as described in claim 1.
3. A reagent for detecting the methylation level of the CpG region as described in claim 1, characterized in that, The reagents include two sets of specific primer and probe sets, one set of internal reference gene ACTB primer and probe sets, and blocking oligonucleotides, which are used for specific amplification and detection of methylation target sequences of the KC group NH5 gene after sulfite treatment; The upstream primer, downstream primer, and probe sequences of the first set of specific primers and probes are as follows: Upstream primer: 5'-GTGTTTCGCGGAGTTTGTAGT-3'; Downstream primer: 5'-CGCCGCTACCCAAACTAT-3'; Probe: 5'-TCGAGTTTCGTGTGCGGTATCG-3'; The upstream primer, downstream primer, and probe sequences of the second set of specific primers and probes are as follows: Upstream primer: 5'-GTAGGCGTATTGTGTTTCGC-3'; Downstream primer: 5'-CGCCGCTACCCAAACTATAA-3'; Probe: 5'-TCGAGTTTCGTGTGCGGTATCG-3'; The upstream primer, downstream primer, and probe sequences of the ACTB internal reference gene primer and probe set are as follows: Upstream primer: 5'-AGTAAGTTTTTTGGATTGTGAAT-3'; Downstream primer: 5'-CAATAAAACCTACTCCTCCCTT-3'; Probe: 5'-CCACCCAACACACAATAACAAACACA-3'; The sequence of the blocking oligonucleotide is: 5'-TGTGGAGTTTGTAGTTTTTGAGTTTTGTGTGTGG-3'; The two sets of specific primer and probe sets share the same blocking oligonucleotide.
4. The reagent according to claim 3, characterized in that, The reagent is suitable for detecting the target region using one or more of the following methods: methylation-specific PCR, bisulfite sequencing, methylation-specific microarray, whole-genome methylation sequencing, pyrosequencing, methylation-specific high-performance liquid chromatography, methylation-specific high-resolution melting curve method, methylation-sensitive restriction endonuclease method, and methylation detection platform based on real-time quantitative PCR.
5. The reagent according to claim 3, characterized in that, It also includes system comparisons; The systemic controls included sulfite-treated colorectal cancer cell line DNA as a positive control and peripheral blood genomic DNA from healthy individuals as a negative control.
6. The use of a reagent for detecting the methylation level of the CpG region of claim 1 in the preparation of a diagnostic kit for colorectal cancer or advanced adenoma.
7. The application according to claim 6, characterized in that, Patients with colorectal cancer or advanced adenoma had significantly higher average methylation levels at at least eight CpG sites within the CpG region than healthy individuals.
8. The application according to claim 6, characterized in that, The samples used for detecting the methylation level of the CpG region were DNA that had undergone sulfite conversion.
9. The application according to claim 8, characterized in that, The test samples include colorectal cancer tissue, adjacent tissue, plasma, serum, feces, or saliva.
10. The application according to claim 6, characterized in that, The application is based on Taqman qPCR detection technology.
